ArticleJournal of cellular and molecular medicine2025
Zerumbone Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing the NLRP3/Caspase-1/GSDMD Signalling Pathway.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Zingerone alleviates acute seizures by reducing intrinsic hippocampal neuronal excitability in a rat model of temporal lobe epilepsy.Frontiers in neuroscience · 2026Article
- Zerumbone Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing the NLRP3/Caspase-1/GSDMD Signalling Pathway.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A cyclic sesquiterpene with 11 carbon atoms is the primary component of essential oils from the wild ginger species, Zingiber zerumbet. It exhibits pharmacological effects, including anti-inflammatory and antioxidant properties. However, limited information exists regarding its role in pyroptosis during acute lung injury (ALI). Herein, we investigated how zingerone affects pyroptosis in a murine lipopolysaccharide (LPS)-induced ALI model established via intraperitoneal zerumbone (Zer) administration. Bronchoalveolar lavage fluid, serum, and lung tissue samples were collected after 24 h. Haematoxylin and eosin staining was performed to assess lung tissue damage. Western blot analysis and real-time quantitative polymerase chain reaction (qRT-PCR) were used to quantify protein expression levels associated with pyroptosis. Before LPS exposure, mouse alveolar epithelial (MLE)-12 cells were pretreated with 10 μM Zer for 2 h and then incubated with 1 ng/mL LPS for an additional 24 h. Zer treatment reduced lung tissue injury, inflammation, and oxidative stress in model mice. Zer counteracted pyroptosis in the alveolar epithelial cells of these mice. In MLE-12 cells, Zer significantly inhibited oxidative stress and inflammation. Zer suppressed NLRP3/Caspase-1/GSDMD signalling, pivotal in pyroptosis, mitigating ALI progression. A potential novel therapeutic agent for ALI inhibited the NLRP3/GSDMD signalling pathway involved in pyroptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.